CD8A and neoplasm: Similarly, depletion of senescent cancer‐associated fibroblasts (CAFs) using the senolytic drug ABT‐199 (venetoclax) increases the proportion of activated CD8+ T cells, and its combination with immune checkpoint therapy significantly reduces tumor burden (Assouline et al. 2024).